News at CenExel

March 24, 2023

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...

December 30, 2022

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...

November 29, 2022

CenExel CNS Opens Center in Los Alamitos, California

Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS...

June 16, 2022

CenExel Acquires Apex Innovative Sciences

Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...